NHP2调控肝癌细胞衰老机制的生物信息学分析

doi:10.19586/j.2095-2341.2023.0108

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 141-148.DOI: 10.19586/j.2095-2341.2023.0108

• 研究论文 • 上一篇

NHP2调控肝癌细胞衰老机制的生物信息学分析

黄师¹^,²(), 莫茵茵¹, 罗绿景¹, 刘会婷¹, 陈峥宇¹, 李根亮¹()

^1.右江民族医学院，广西百色 533000
^2.右江民族医学院附属医院麻醉科，广西百色 533000

收稿日期:2023-09-12 接受日期:2023-12-08 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 李根亮
作者简介:黄师 E-mail: shihuang_mail@foxmail.com；
基金资助:
广西2023年研究生教育创新计划项目(YCSW2023502);2022年百色市科技计划项目区域多发病联合专项(百科20224148);2023年右江民族医学院硕士研究生创新项目(YXCXJH2023018)

Bioinformatics Analysis on the Regulation Mechanism of NHP2 on Hepatocellular Carcinoma Senescence

Shi HUANG¹^,²(), Yinyin MO¹, Lyujing LUO¹, Huiting LIU¹, Zhengyu CHEN¹, Genliang LI¹()

^1.Youjiang Medical College for Nationalities，Guangxi Baise 533000，China
^2.Affiliated Hospital of Youjiang Medical University for Nationalities，Guangxi Baise 533000，China

Received:2023-09-12 Accepted:2023-12-08 Online:2024-01-25 Published:2024-02-05
Contact: Genliang LI

摘要/Abstract

摘要：

为了探讨核糖核蛋白NHP2在肝细胞癌（hepatocellular carcinoma, HCC）中的表达情况，了解其与疾病进展与预后的关系，通过Quick Go、GEPIA 2在线数据库筛选HCC细胞衰老的差异表达基因并确定了研究对象基因NHP2；进一步使用STRING、TIMER 2.0、UALCAN数据库等生物信息学方法分析NHP2在泛癌中的差异表达以及在肝癌和其他泛癌中病理进展过程中的相关性，并预测预后生存关系；使用miRNet数据库分析其靶向miRNAs和lncRNAs，应用Cytoscape v3.8.0绘制可能的CeRNAs调控网络图。结果显示，在线数据库检索到细胞衰老相关生物学过程相关基因113个，HCC差异表达基因2 206个，共有19个差异表达基因参与了肝癌细胞衰老的生物学过程。其中，NHP2在包括HCC的多种癌症中显著高表达，NHP2高表达的肝癌人群预后较差，具有统计学差异。NHP2基因编码的互作蛋白有10个，主要参与了1个信号通路（KEGG信号通路）、6个分子功能（molecular function，MF）、11个细胞组分（cellular component，CC）和7个生物学过程（biological process，BP）。结果预测出NHP2靶向miRNAs有2个，lncRNAs有57个。研究结果表明，NHP2在包括HCC的多种肿瘤中高表达，且根据患者的年龄、分期等状态有明显差异，在HCC增殖和衰老过程中，可能通过lncRNAs/miR-1-3p/NHP2或lncRNAs/miR-124-3p/NHP2调控轴进行调节，是HCC预后的预测因子和潜在治疗靶点。

关键词: 核糖核蛋白, 细胞衰老, 肝细胞癌, 生物信息学

Abstract:

To investigate the expression of ribonucleo protein NHP2 in hepatocellular carcinoma （HCC） and to explore the relationship with disease progression and prognosis. Differentially expressed genes of HCC were screened by Quick Go and GEPIIA 2 online databases， and NHP2 was identified as object of study. Furthermore， bioinformatics methods such as STRING， TIMER 2.0， UALCAN database were used to analyze the differential expression of NHP2 in pancreatic cancer and its correlation with pathological progress in HCC and other pancreatic cancers， and to predict the relationship between prognosis and survival. The target miRNAs and lncRNAs were analysed with the miRNet database， the possible regulatory network of CeRNAs was mapped by Cytescape v3.8.0. Results showed that， 113 genes related to cell aging and 2 206 differentially expressed genes（DEGs） in HCC were found in the online database. 19 DEGs were involved in the biological process of cell aging in HCC. Among them， NHP2 is significantly highly expressed in a variety of cancers including HCC， and the prognosis of HCC with high NHP2 expression is poor in statistical difference. There are 10 interacting proteins encoded by the NHP2 gene， it is mainly involved in 1 signalling pathway （KEGG）， 6 molecular functions （MF）， 11 cellular components （CC） and 7 biological processes （BP）. Two NHP2-targeting miRNAs and 57 NHP2-targeting lncRNAs had been predicted. The results indicated that， NHP2 is highly expressed in a variety of tumors， including HCC， and is significantly different in age and stage of patients with a variety of tumors. During the proliferation and senescence of HCC， it may be regulated by the regulatory axis of lncRNAs/miR-1-3p/NHP2 or lncRNAs/miR-124-3p/NHP2 and be a prognostic predictor and a potential therapeutic target of HCC.

Key words: NHP2, cellular senescence, hepatocellular carcinoma, bioinformatics

中图分类号:

Q279

黄师, 莫茵茵, 罗绿景, 刘会婷, 陈峥宇, 李根亮. NHP2调控肝癌细胞衰老机制的生物信息学分析[J]. 生物技术进展, 2024, 14(1): 141-148.

Shi HUANG, Yinyin MO, Lyujing LUO, Huiting LIU, Zhengyu CHEN, Genliang LI. Bioinformatics Analysis on the Regulation Mechanism of NHP2 on Hepatocellular Carcinoma Senescence[J]. Current Biotechnology, 2024, 14(1): 141-148.

图/表 9

图1 Quick Go细胞衰老基因与GEPIA 2 HCC差异表达基因的韦恩图

Fig. 1 Venn diagram of cell senescence gene in Quick Go base and DEGs in GEPIIA 2 of HCC

图2 UALCAN数据库中NHP2在HCC中的表达情况注：两组数据在P<0.001水平有统计学差异。

Fig. 2 The expression of NHP2 in HCC in UALCAN database

图3 TIMER 2.0数据库中NHP2在多种肿瘤中的表达情况

Fig. 3 Expression of NHP2 in a variety of tumors in TIMER 2.0 database

图4 NHP2的互作蛋白

Fig. 4 The PPI of NHP2

图5 NHP2基因及其相关基因的功能富集分析

Fig. 5 Functional enrichment analysis of NHP2 gene and its related genes

图6 NHP2在HCC不同状态的对比结果

Fig. 6 Comparison of NHP2 in different states of HCC

图7 NHP2在泛癌的疾病分期对比结果

Fig. 7 Comparison of NHP2 in disease staging in pancarcinoma

图8 NHP2在HCC中的预后生存分析

Fig. 8 Prognostic survival analysis of NHP2 in HCC

图9 NHP2的ceRNA调控网络图

Fig. 9 CeRNA regulatory network diagram of NHP2

参考文献 27

1	秦叔逵,任正刚,曾昭冲,等.原发性肝癌诊疗指南(2022年版)[J].肿瘤综合治疗电子杂志,2022,8(2):16-53.
	QIN S, REN Z, ZENG Z,et al..Guidelines for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J. Multidiscip. Cancer Manag. Electron. Version, 2022, 8(2): 16-53.
2	雷倩,夏机良,冯湘玲,等.NEK2通过抵抗肝癌细胞衰老促进肝癌进展[J].中南大学学报(医学版),2022,47(2):153-164.
	LEI Q, XIA J L, FENG X L, et al.. NEK2 promotes the progression of liver cancer by resisting the cellular senescence[J]. J. Cent. South Univ. Med. Sci., 2022, 47(2): 153-164.
3	ROAKE C M, ARTANDI S E. Regulation of human telomerase in homeostasis and disease[J]. Nat. Rev. Mol. Cell Biol., 2020, 21(7): 384-397.
4	RAGHUNANDAN M, GEELEN D, MAJEROVA E, et al.. NHP2 downregulation counteracts hTR-mediated activation of the DNA damage response at ALT telomeres[J/OL]. EMBO J., 2021, 40(6): e106336[2023-11-20]. .
5	MALIŃSKI B, VERTEMARA J, FAUSTINI E, et al.. Novel pathological variants of NHP2 affect N-terminal domain flexibility, protein stability, H/ACA Ribonucleoprotein (RNP) complex formation and telomerase activity[J]. Hum. Mol. Genet., 2023, 32(19): 2901-2912.
6	LIU L, SHENG Y, WANG C Y, et al.. A novel mutation (p.Y24N) inNHP2 leads to idiopathic pulmonary fibrosis and lung carcinoma chronic obstructive lung disease by disrupting the expression and nucleocytoplasmic localization of NHP2[J/OL]. Biochim. Biophys. Acta Mol. Basis. Dis., 2023, 1869(5): 166692[2023-11-20]. .
7	SUNG H, FERLAY J, SIEGEL R L, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J. Clin., 2021, 71(3): 209-249.
8	黄家利,徐畅,吴虹,等.肝细胞癌中HP1BP3的表达及其对细胞恶性生物学行为的影响[J].临床与实验病理学杂志,2022,38(6):653-658.
	HUANG J L, XU C, WU H, et al.. Expression of HP1 BP3 in hepatocellular carcinoma and its effect on malignant biological behaviors of the tumor cells[J]. Chin. J. Clin. Exp. Pathol., 2022, 38(6): 653-658.
9	陶莹,廖长秀.新兴免疫阻断分子在肝细胞癌发生发展中的作用[J].临床肝胆病杂志,2023,39(4):948-955.
	TAO Y, LIAO C X. Role of new potential immune blocking molecules in the development and progression of hepatocellular carcinoma[J]. J. Clin. Hepatol., 2023, 39(4): 948-955.
10	崔晓东,邹娇娇,王转花.细胞衰老与癌症治疗[J].中国生物化学与分子生物学报,2020,36(2):119-126.
	CUI X D, ZOU J J, WANG Z H. Cell senescence and cancer therapy[J]. Chin. J. Biochem. Mol. Biol., 2020, 36(2): 119-126.
11	CAO H, ZHAI Y, JI X, et al.. Noncoding telomeric repeat-containing RNA inhibits the progression of hepatocellular carcinoma by regulating telomerase-mediated telomere length[J]. Cancer Sci., 2020, 111(8): 2789-2802.
12	TANG S, WU W, WAN H, et al.. Knockdown of NHP₂ inhibits hepatitis B virus X protein-induced hepatocarcinogenesis via repressing TERT expression and disrupting the stability of telomerase complex[J]. Aging Albany NY, 2020, 12(19): 19365-19374.
13	NAULT J C. Pathogenesis of hepatocellular carcinoma according to aetiology[J]. Best Pract. Res. Clin. Gastroenterol., 2014, 28(5): 937-947.
14	KIM Y J, YOO J E, JEON Y, et al.. Suppression of PROX1-mediated TERT expression in hepatitis B viral hepatocellular carcinoma[J]. Int. J. Cancer, 2018, 143(12): 3155-3168.
15	JAISWAL R K, YADAVA P K. Assessment of telomerase as drug target in breast cancer[J/OL]. J. Biosci., 2020, 45(1): 72[2023-11-20]. .
16	DOGAN F, BIRAY AVCI C. Correlation between telomerase and mTOR pathway in cancer stem cells[J]. Gene, 2018, 641: 235-239.
17	DRATWA M, WYSOCZAŃSKA B, ŁACINA P, et al.. TERT-regulation and roles in cancer formation[J/OL]. Immunol, 2020, 11: 589929[2023-11-20]. .
18	LI Y, TERGAONKAR V. Telomerase reactivation in cancers: mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters[J]. Transcription, 2016, 7(2): 44-49.
19	ZHEN H, DU P, YI Q, et al.. LINC00958 promotes bladder cancer carcinogenesis by targeting miR-490-3p and AURKA[J/OL]. BMC Cancer, 2021, 21(1): 1145[2023-11-20]. .
20	HUANG C S, TSAI C H, YU C P, et al.. Long noncoding RNA LINC02470 sponges microRNA-143-3p and enhances SMAD3-mediated epithelial-to-mesenchymal transition to promote the aggressive properties of bladder cancer[J/OL]. Cancers Basel, 2022, 14(4): 968[2023-11-20]. .
21	吴潇芸,吴林秀,张丽娣,等.LINC00839靶向调控miR-124-3p对膀胱癌细胞生物学行为的影响[J].天津医药,2023,51(5):464-468.
	WU X Y, WU L X, ZHANG L D, et al.. The effect of LINC00839 targeting regulation of miR-124-3p on biological behaviors of bladder cancer cells[J]. Tianjin Med. J., 2023, 51(5): 464-468.
22	苏敏,王文祥,唐金明.circHIPK3通过调控miR-124-3p/EZH2促进食管鳞状细胞癌细胞恶性生物学行为[J].临床与实验病理学杂志,2021,37(12):1405-1411.
	SU M, WANG W X, TANG J M. CircHIPK3 promotes malignant biological behavior of esophageal squamous cell carcinoma cells through regulation of miR-124-3p/EZH2[J]. Chin. J. Clin. Exp. Pathol., 2021, 37(12): 1405-1411.
23	周立飞,高跃丽,耿欣,等. MiR-124-3p和SEPT9与宫颈癌患者临床表现的相关性分析[J].中国优生与遗传杂志,2023,31(1):64-69.
	ZHOU L F, GAO Y L, GENG X, et al.. Correlation analysis of miR-124-3p and SEPT9 with clinical manifestations of cervical cancer patients[J]. Chin. J. Birth Health Hered., 2023, 31(1): 64-69.
24	李敬霞,刘艳.LncRNA PTPRG-AS1通过靶向miR-124-3p调控肝癌细胞凋亡和放射敏感性的研究机制[J].现代肿瘤医学,2021,29(10):1676-1682.
	LI J X, LIU Y. LncRNA PTPRG-AS1 regulates apoptosis and radiosensitivity of hepatoma cells by targeting miR-124-3p [J]. J. Mod. Oncol., 2021, 29(10): 1676-1682.
25	WU Q, ZHONG H, JIAO L, et al.. MiR-124-3p inhibits the migration and invasion of Gastric cancer by targeting ITGB3[J/OL]. Pathol. Res. Pract., 2020, 216(1): 152762[2023-11-20]. .
26	ZHAO J T, CHI B J, SUN Y, et al.. LINC00174 is an oncogenic lncRNA of hepatocellular carcinoma and regulates miR-320/S100A10 axis[J]. Cell Biochem. Funct., 2020, 38(7): 859-869.
27	张英英.lncRNA CYTOR、miRNA378a与FEN1基因共同调控肝癌细胞恶性生物学行为的机制研究[D].郑州:郑州大学,2020.

[1]	胡文冉, 郝晓燕, 赵准, 邵武奎, 高升旗, 李建平, 黄全生. 棉花CAD基因家族的生物信息学分析[J]. 生物技术进展, 2023, 13(3): 412-424.
[2]	王彦容, 郭元彪. 基于铁死亡相关LncRNA构建肝细胞癌预后模型的研究[J]. 生物技术进展, 2023, 13(3): 473-481.
[3]	李冠群, 梁超杰, 夏峰. 基于甲基化组学数据建立并验证肝细胞癌预后评价模型研究[J]. 生物技术进展, 2023, 13(2): 282-290.
[4]	朱兴墅, 黄军杰, 翁才明, 刘旺武, 陈永元, 陈惠燕, 赵虎, 王瑜, 林承志. 基于生物信息学分析林奇综合征相关结直肠癌关键Hub基因的筛选与功能富集分析[J]. 生物技术进展, 2023, 13(2): 291-297.
[5]	李凤梅, 汤雪媛, 焦高洋, 齐玉亭, 杜献婷, 鲍倩倩, 张梦, 徐小博, 徐鑫, 张艳芳. 金银花花形基因的发掘及生物信息学分析[J]. 生物技术进展, 2023, 13(1): 90-101.
[6]	于敏, 王敏, 魏延焕, 刘毅毅. SARS-CoV-2病毒感染潜在关键分子生物标志物及免疫浸润特征分析[J]. 生物技术进展, 2022, 12(5): 760-768.
[7]	许广平,张志勇,任忠宏,张志伟. 黑鲷ELO基因编码蛋白结构与功能的生物信息学分析[J]. 生物技术进展, 2021, 11(3): 344-352.
[8]	许杰,王可飞,魏晓晶,龚莉欣,焦阳,邱录贵,郝牧. 基于生物信息学分析SCHIP1在急性髓系白血病中的表达及其临床意义[J]. 生物技术进展, 2020, 10(4): 417-425.
[9]	张凤丽,杨雅麟,夏锐,高辰辰,李栋,冉超,张震,张洪玲,周志刚. 吉陶单极虫可分泌蛋白酶基因的克隆与生物信息学分析[J]. 生物技术进展, 2019, 9(4): 375-383.
[10]	徐长禄,赵艳红,马艺戈,王冰蕊,王鼎,郭青,佟静媛,高洁,李亚朴,刘金花,石莉红. 利用生物信息学方法解析自噬相关基因在人体红细胞终末分化各阶段的动态表达[J]. 生物技术进展, 2019, 9(3): 271-276.
[11]	孙静娟,邱景璇,曾海娟,丁承超,王广彬,李杰,王淑娟,刘箐. 单增李斯特菌prsA1基因的截短表达、纯化及多克隆抗体的制备[J]. 生物技术进展, 2018, 8(3): 254-260.
[12]	姜志磊,周琳,武奉慈,宋新元. 玉米扩展蛋白Expansin基因家族定位及基因表达模式分析[J]. 生物技术进展, 2018, 8(1): 34-40.
[13]	张茂娜,姜亮,张焱. 硒代谢网络与硒蛋白质组的生物信息学研究进展[J]. 生物技术进展, 2017, 7(5): 537-544.
[14]	康爽,贺红霞,王铭,郭嘉,薛晶. 杏蔗糖转运蛋白基因PaSUC4的获得及其生物信息学分析[J]. 生物技术进展, 2016, 6(2): 105-112.
[15]	王姣姣,耿圆圆,张家耀,姜伟. 肝细胞癌循环肿瘤细胞标志物及检测方法研究进展[J]. 生物技术进展, 2015, 5(2): 113-119.

NHP2调控肝癌细胞衰老机制的生物信息学分析

Bioinformatics Analysis on the Regulation Mechanism of NHP2 on Hepatocellular Carcinoma Senescence

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价